A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Latest Information Update: 14 May 2025
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
Most Recent Events
- 08 May 2025 Planned End Date changed from 31 Dec 2024 to 6 May 2026.
- 19 Jan 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2024.
- 14 Feb 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2021.